156 related articles for article (PubMed ID: 2670213)
1. Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.
Sznol M; Dutcher JP; Atkins MB; Rayner AR; Margolin KA; Gaynor ER; Weiss GR; Aronson F; Parkinson DR; Hawkins MJ
Cancer Treat Rev; 1989 Jun; 16 Suppl A():29-38. PubMed ID: 2670213
[No Abstract] [Full Text] [Related]
2. [Systemic therapy of metastatic malignant melanoma].
Stahel RA; Martz G
Schweiz Rundsch Med Prax; 1988 Apr; 77(17):459-62. PubMed ID: 3259710
[No Abstract] [Full Text] [Related]
3. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
Ghosh AK; Mellor M; Prendiville J; Thatcher N
Br J Cancer; 1990 Mar; 61(3):471-4. PubMed ID: 2328217
[TBL] [Abstract][Full Text] [Related]
4. Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
Schrader AJ
Anticancer Drugs; 2000 Mar; 11(3):143-8. PubMed ID: 10831272
[TBL] [Abstract][Full Text] [Related]
5. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
Legha SS; Buzaid AC
Semin Oncol; 1993 Dec; 20(6 Suppl 9):27-32. PubMed ID: 8054006
[No Abstract] [Full Text] [Related]
6. [A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].
Keilholz U; Welters H; Dummer R; Tilgen W; Hunstein W
Hautarzt; 1988 Jun; 39(6):378-81. PubMed ID: 3261288
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
9. Studies confirm value of IL-2/LAK treatment.
Wittenberg C
J Natl Cancer Inst; 1989 May; 81(10):732-3. PubMed ID: 2785604
[No Abstract] [Full Text] [Related]
10. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA
Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556
[TBL] [Abstract][Full Text] [Related]
11. Implementation of an RIL-2/LAK cell clinical trial: a nursing perspective.
Corey BS; Collins JL
Oncol Nurs Forum; 1986; 13(6):31-6. PubMed ID: 3540867
[No Abstract] [Full Text] [Related]
12. New approaches to the systemic treatment of melanoma.
Chowdhury S; Vaughan MM; Gore ME
Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
14. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
15. Metastatic melanoma: chemotherapy.
Bajetta E; Del Vecchio M; Bernard-Marty C; Vitali M; Buzzoni R; Rixe O; Nova P; Aglione S; Taillibert S; Khayat D
Semin Oncol; 2002 Oct; 29(5):427-45. PubMed ID: 12407508
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.
Dutcher JP; Creekmore S; Weiss GR; Margolin K; Markowitz AB; Roper M; Parkinson D; Ciobanu N; Fisher RI; Boldt DH
J Clin Oncol; 1989 Apr; 7(4):477-85. PubMed ID: 2647913
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of melanoma].
Dréno B; Wallon-Dumont G
Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
[TBL] [Abstract][Full Text] [Related]
19. The role of biological response modifiers in metastatic renal cell carcinoma.
Muss HB
Semin Oncol; 1988 Oct; 15(5 Suppl 5):30-4. PubMed ID: 2461595
[No Abstract] [Full Text] [Related]
20. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
Dillman RO; Oldham RK; Barth NM; Birch R; Arnold J; West WH
J Natl Cancer Inst; 1990 Aug; 82(16):1345-9. PubMed ID: 2199682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
